Mindfulness-based cognitive therapy for patients with chronic, treatment-resistant depression: A pragmatic randomized controlled trial by Cladder-Micus, M.B. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/195861
 
 
 
Please be advised that this information was generated on 2019-06-02 and may be subject to
change.
Received: 30 August 2017 Revised: 25May 2018 Accepted: 29May 2018
DOI: 10.1002/da.22788
R E S E A RCH ART I C L E
Mindfulness-based cognitive therapy for patients with chronic,
treatment-resistant depression: A pragmatic randomized
controlled trial
Mira B. Cladder-Micus1,2,3 Anne E.M. Speckens3 JannaN. Vrijsen2,4
A. Rogier T. Donders5 Eni S. Becker1 Jan Spijker1,2
1Behavioural Science Institute, RadboudUniver-
sityNijmegen, Nijmegen, TheNetherlands
2Depression Expertise Centre, Pro Persona
Mental HealthCare, Nijmegen, TheNetherlands
3Department of Psychiatry, RadboudUniversity
Medical Center, Nijmegen, TheNetherlands
4Department of Psychiatry, Donders Insti-
tute for Brain, Cognition andBehaviour, Rad-
boudUniversityMedical Center, Nijmegen, The
Netherlands
5Department forHealth Evidence, Radboud
UniversityMedical Center, Nijmegen,
TheNetherlands
Correspondence
MiraB.Cladder-Micus,DepartmentofPsychi-
atry, RadboudUniversityMedicalCenter, P.O.
Box9101, Internal PostalCode966, 6500HB
Nijmegen, TheNetherlands.
Email:m.cladder-micus@psych.ru.nl
Funding information
FondsPsychischeGezondheid,Grant/Award
Number: 20116630
Background: Chronic and treatment-resistant depressions pose serious problems in mental
health care. Mindfulness-based cognitive therapy (MBCT) is an effective treatment for remitted
and currently depressed patients. It is, however, unknownwhetherMBCT is effective for chronic,
treatment-resistant depressed patients.
Method: A pragmatic, multicenter, randomized-controlled trial was conducted comparing
treatment-as-usual (TAU) with MBCT + TAU in 106 chronically depressed outpatients who pre-
viously received pharmacotherapy (≥4weeks) and psychological treatment (≥10 sessions).
Results: Based on the intention-to-treat (ITT) analysis, participants in the MBCT + TAU condi-
tion did not have significantly fewer depressive symptoms than those in the TAU condition (–3.23
[–6.99 to 0.54], d=0.35,P=0.09) at posttreatment. However, compared to TAU, theMBCT+TAU
group reported significantly higher remission rates (𝜒2(2)= 4.25, 𝜑= 0.22, P= 0.04), lower levels
of rumination (–3.85 [–7.55 to –0.15], d= 0.39, P= 0.04), a higher quality of life (4.42 [0.03–8.81],
d = 0.42, P = 0.048), more mindfulness skills (11.25 [6.09–16.40], d = 0.73, P < 0.001), and more
self-compassion (2.91 [1.17–4.65], d = 0.64, P = 0.001). The percentage of non-completers in the
MBCT + TAU condition was relatively high (n = 12, 24.5%). Per-protocol analyses revealed that
those who completed MBCT + TAU had significantly fewer depressive symptoms at posttreat-
ment compared to participants receiving TAU (–4.24 [–8.38 to –0.11], d= 0.45, P= 0.04).
Conclusion: Although the ITT analysis did not reveal a significant reduction in depressive symp-
toms of MBCT + TAU over TAU, MBCT + TAU seems to have beneficial effects for chronic,
treatment-resistant depressed patients in terms of remission rates, rumination, quality of life,
mindfulness skills, and self-compassion. Additionally, patients who completed MBCT showed
significant reductions in depressive symptoms. Reasons for non-completion should be further
investigated.
K EYWORDS
depressive disorder, mindfulness, quality of life, randomized controlled trial, treatment-resistant
depression
1 INTRODUCTION
Major depressive disorder is one of the leading causes of disability
worldwide (Lopez, Mathers, Ezzati, Jamison, &Murray, 2006). Despite
evidence-based treatments, about 20% of all depressed patients
develop a chronic course (Kessler et al., 2003), typically defined as
a period of 2 years or longer of depressive symptoms (DSM-IV-TR,
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2000). Chronic depression not only affects the personal life of a
patient, but is also associated with high costs for society in terms of
health care costs and workplace losses (Pincus, 2001). Unfortunately,
a large number of chronically depressed patients do not respond
to treatment (Torpey & Klein, 2008). Therefore, novel treatment
strategies for this severely ill population are much needed (Cuijpers,
Huibers, & Furukawa, 2017).
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Surprisingly, no unified definition of treatment-resistant depres-
sion exists. Staging methods to measure treatment resistance mostly
focus on the number of biological treatment steps (Trevino, McClin-
tock, Fischer, Vora, &Husain, 2014). In linewith these stagingmethods,
most clinical trials define a depressive episode as treatment-resistant
if two or more trials with antidepressant medication were unsuccess-
ful (Rush, Thase, & Dubé, 2003; Trevino et al., 2014). However, this
definition conflicts with multidisciplinary treatment guidelines (NICE,
2009), which state that depressed patients with moderate to severe
symptoms should receive a combination of psychological and phar-
macological treatments. Therefore, a new staging method to measure
treatment resistance was developed, which is termed as the “Dutch
Measure for quantification of Treatment Resistance in Depression”
(DM-TRD) (Peeters et al., 2016). In contrast to previous staging meth-
ods (Fekadu, Wooderson, Donaldson, et al., 2009; Fekadu, Wooder-
son, Markopoulou, & Cleare, 2009; Petersen et al., 2005; Souery et al.,
1999; Thase & Rush, 1997), the DM-TRD not only focuses on biolog-
ical treatments but also includes evidence-based psychological treat-
ments. For these reasons, we have chosen to apply the criteria of the
DM-TRD for treatment resistance in the current study.
Mindfulness-based cognitive therapy (MBCT) is an 8-week group
training that combines mindfulness meditation techniques with ele-
ments of cognitive-behavioral therapy (Segal, Williams, & Teasdale,
2012). MBCT teaches participants to recognize and disengage from
maladaptive automatic cognitive patterns, and to develop a nonjudg-
mental and compassionate attitude toward their own cognitions and
feelings. MBCT has been demonstrated to be effective in reducing
relapse (Kuyken et al., 2016). In addition, it has been shown that
MBCT reduces depressive symptoms in currently depressed patients
(Strauss, Cavanagh, Oliver, & Pettman, 2014). Preliminary studies
(Barnhofer Crane, Hargus, Amarasinghe, Winder, & Williams, 2009;
Eisendrath et al., 2008; Kenny & Williams, 2007) have even found
beneficial effects of MBCT for patients with chronic or treatment-
resistant depression. In line with these findings, in a recent random-
ized controlled trial (RCT) of Eisendrath et al. (2016) in treatment-
resistant depressed patients, MBCT was demonstrated to be superior
to an active control group matched on treatment intensity. However,
partly contrasting results were found by Michalak, Probst, Heidenre-
ich, Bissantz, and Schramm (2016) in an RCT comparing MBCT with
Cognitive Behavioural Analysis System of Psychotherapy (CBASP) and
treatment-as-usual (TAU) in chronically depressed patients. CBASP
is a psychological treatment with a strong interpersonal orientation
that focuses on overcoming the learned helplessness of the patient
by teaching patients that their own behavior affects others and them-
selves (McCullough, 2003). Michalak et al. (2016) concluded that
MBCT was inferior to CBASP, and MBCT was superior to TAU only at
one treatment site.
Importantly, all available controlled studies about MBCT for
treatment-resistant depression focused on pharmacoresistant
depressed patients (Eisendrath et al., 2008, 2016). It therefore
remains unclear whether MBCT is effective in chronically depressed
patientswho have been treated according to treatment guidelines (i.e.,
received evidence-based psychological treatment and pharmacother-
apy) but have not responded.
The aim of the current study was to investigate the effectiveness
of MBCT + TAU versus TAU only for chronically depressed patients
with current moderate to severe depressive symptoms who have
not responded to previous pharmacotherapy and evidenced-based
psychological treatments, that is, cognitive behavioral therapy (CBT)
or interpersonal therapy (IPT). The primary outcome measure was
the level of depressive symptoms. Secondary outcomemeasures were
remission rates, rumination, quality of life, mindfulness skills, and
self-compassion. Additionally, we examined the following variables
as potential moderators of treatment effect gender, age, childhood
trauma, number of previous episodes, duration of current depressive
episode, treatment resistance, baseline levels of depressive symptoms,
rumination, mindfulness skills, and self-compassion.
2 METHOD
2.1 Design
This trialwas anopen-labeled,multicenterRCT comparing twogroups:
MBCT + TAU and TAU. Methods and procedures are fully described
in the published protocol (Cladder-Micus et al., 2015) and are sum-
marized below. All participants gave written informed consent and
the study was approved by the Medical Ethical Committee Arnhem-
Nijmegen (number 2012/339).
2.2 Participants
Participants (N = 106) were recruited at different locations of a
local mental health institute (Pro Persona) and a university medical
center (Radboud University Medical Center, Centre for Mindful-
ness). Participants were referred by mental health care professionals
or recruited via flyers, posters, and websites. Clinicians were also
explicitly asked to screen their caseload for potentially eligible par-
ticipants. A depressive episode was defined as “chronic” if symptoms
persisted for ≥12 months, because research has shown that chances
of recovery decrease substantially after this period (Spijker et al.,
2002). Inclusion criteria were (a) age ≥ 18, (b) current depressive
episode according to DSM-IV criteria with a duration of ≥12 months,
(c) moderate to high levels of depressive symptoms (Inventory of
Depressive Symptomatology-Self-Report [IDS-SR] ≥ 21), (d) at least
one adequate trial of antidepressant medication during the current
episode (defined as appropriate doses of antidepressant medication
for ≥4 weeks or patient's refusal to use medication contrary to the
advice of a psychiatrist), and (e) previous psychological treatment
during the current episode (defined as ≥10 sessions of CBT or IPT
or < 10 sessions if discontinued because of patient's withdrawal).
Exclusion criteria were as follows: (a) current psychotic symptoms;
(b) lifetime bipolar disorder; (c) current alcohol or drug dependence;
(d) recent electro convulsive therapy (< 3 months ago); (e) current
somatic disorder partly explaining depressive symptoms; (f) physical,
linguistic, cognitive, or intellectual impairments, which might interfere
with participation in MBCT or assessments; and (g) previous MBCT
training. Baseline characteristics can be found in Table 1.
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TABLE 1 Demographic characteristics, clinical characteristics, and
baseline levels of symptoms in both conditions displayed as number
(percentage) unless otherwise specifieda
Whole sample TAU MBCT+ TAU
n= 106 n= 57 n= 49
Demographic characteristics
Female 66 (62) 34 (60) 32 (65)
Age,M (SD), years 47.1 (10.25) 47.33 (10.9) 46.86 (9.53)
Education
Low 34 (32) 18 (32) 16 (32)
Medium 29 (27) 20 (35) 9 (18)
High 35 (33) 18 (32) 17 (35)
Marital status
Single/widowed/
divorced
45 (43) 28 (49) 17 (35)
Married/
cohabitating
44 (42) 24 (42) 20 (41)
Employment
Full time 10 (9.4) 7 (12.3) 3 (6.1)
Part time 19 (17.9) 7 (12.3) 12 (24.5)
Unemployed 67 (63.2) 40 (70.2) 27 (55.1)
Retired 3 (2.8) 1 (1.8) 1 (2)
Clinical characteristics
n= 104 n= 56 n= 48
Previous episodes,M
(SD)
2.69 (3.37) 2.68 (3.96) 2.71 (2.56)
Age of onset,M (SD),
years
29.84 (13.16) 31.75 (12.70) 27.61 (13.48)
n= 103 n= 56 n= 47
Duration episodeb, M
(SD), months
63.59 (70.74) 60.54 (65.42) 67.23 (77.76)
Current episode≥ 2
years
85 (80) 45 (79) 40 (82)
Anxiety disorderc 50 (47) 30 (53) 20 (41)
n= 97 n= 53 n= 44
Psychological
treatment sessions
(CBT/IPT)b,M (SD)
36.29 (49.69) 32.94 (36.27) 40.32 (62.38)
Previous inpatient treatment b
Inpatient 20 (19) 13 (23) 7 (14)
Day-hospital 15 (14) 8 (14) 7 (14)
> 2 AD's current
episode (%)
38.7 36.8 40.8
Medication level at baseline
No AD 23 (22) 14 (25) 9 (18)
1 SSRI 20 (19) 12 (21) 8 (16)
1 TCA/SNRI/other
AD
24 (23) 13 (23) 11 (22)
1MAOI 3 (3) 1 (2) 2 (4)
2 AD's 4 (4) 1 (2) 3 (6)
1 AD+
antipsychotic
21 (20) 11 (19) 10 (20)
1 AD+ lithium 7 (7) 4 (7) 3 (6)
(Continues)
TABLE 1 (Continued)
Whole sample TAU MBCT+ TAU
n= 106 n= 57 n= 49
n= 106 n= 57 n= 49
Treatment-resistance
(DM-TRD),M (SD)
13.92 (2.73) 14.08 (2.71) 13.74 (2.77)
n= 89 n= 52 n= 37
Childhood trauma
(CTQ),M (SD)
49.22 (19.48) 48.77 (17.80) 49.86 (21.64)
Baseline assessment,M (SD)
n= 106 n= 57 n= 49
Depression (IDS-SR) 41.11 (9.37) 42.21 (9.12) 39.83 (9.59)
n= 100 n= 57 n= 43
Rumination (RRS) 56.82 (9.89) 56,89 (10.12) 56.75 (9.69)
Brooding 13.54 (2.94) 13,57 (3.08) 13.51 (2.77)
Reflective 10.79 (3.09) 10,80 (3.37) 10.79 (2.71)
Quality of life
(WHOQoL-BREF)
71.92 (10.24) 70,97 (8.97) 73.18 (11.72)
Physical 18.87 (4.07) 18,59 (3.28) 19.23 (4.94)
Psychological 13.67 (3.07) 13,50 (2.95) 13.88 (3.23)
Social 8.67 (2.34) 8,52 (2.23) 8.86 (2.49)
Environment 26.15 (4.03) 25,82 (3.90) 26.60 (4.22)
n= 99 n= 56 n= 43
Mindfulness (FFMQ) 101.21
(15.27)
100.92
(15.34)
101.60
(15.35)
Observing 21.37 (5.67) 21.27 (5.73) 21.51 (5.66)
Describing 22.50 (6.57) 22.24 (5.64) 22.86 (7.69)
Acting/awareness 19.23 (4.86) 19.18 (4.79) 19.30 (5.04)
Nonjudging 21.37 (6.40) 21.65 (6.78) 21.01 (5.92)
Nonreacting 16.92 (3.91) 16.94 (4.24) 16.31 (3.50)
n= 98 n= 56 n= 42
Self-compassion
(SCS)
17.59 (4.61) 17.63 (5.16) 17.55 (3.88)
Self-kindness 2.67 (1.11) 2.68 (1.14) 2.67 (1.09)
Self-judging 2.99 (1.26) 2.98 (1.28) 3.01 (1.27)
Common humanity 3.01 (1.09) 2.99 (1.13) 3.05 (1.06)
Isolation 2.73 (1.07) 2.79 (1.23) 2.64 (0.81)
Mindfulness 3.17 (1.15) 3.05 (1.45) 3.33 (1.15)
Overidentification 3.03 (1.23) 3.18 (1.34) 2.83 (1.10)
Note. AD, antidepressant; CBT, cognitive behavioral therapy; IPT, interper-
sonal therapy; MAOI, monoamine-oxidase inhibitor; SNRI, serotonin–
norepinephrine reuptake inhibitor; SSRI, serotonin; TCA, tricyclic
antidepressant; IDS-SR, Inventory of Depressive Symptomatology-
Self Report; WHOQoL-BREF, World Health Organisation Quality of
Life Questionnaire; FFMQ, Five Facets Mindfulness Questionnaire; SCS,
Self-Compassion Scale.
aThere were no significant differences between the MBCT + TAU and TAU
condition.
bCurrent depressive episode.
cAt baseline, according to DSM-IV criteria.
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2.3 Procedure
Interested patients received an information letter andwere contacted
via telephone. During a subsequent research interview, theMini Inter-
national Neuropsychiatric Interview (MINI, Sheehan et al., 1998) was
administered to diagnose depressive, anxiety, psychotic, and addictive
disorders according to DSM-IV criteria. In addition, sociodemographic
and clinical characteristics were assessed, including treatment resis-
tance (DM-TRD, Peeters et al., 2016) and childhood trauma (Childhood
Trauma Questionnaire; Bernstein et al., 2003). The DM-TRD includes
domains such as duration and severity of symptoms, comorbid anxiety
disorders, functional impairments, previous biological treatments, and
previous psychological treatments. After completion of the baseline
measures, participants were randomized to MBCT + TAU or TAU only
bymeans of a web-based application that was specifically designed for
this study by an independent statistician. Randomization was 1:1 to
MBCT + TAU or TAU only, stratified for treatment center, and mini-
mized for the severity of depressive symptoms (IDS-SR: 21–31; 32–
39;> 40) and chronicity (1–2 years,≥2 years), without using block ran-
domization. If due to scheduling constraints the time between base-
line assessment and start of MBCT exceeded 4 weeks, a second base-
line assessment was conducted before MBCT started. Participants
assigned to the TAU condition were offered MBCT after completion
of posttreatment measures. Follow-up data were collected at 3 and 6
months after completingMBCT.Additionally, a subsample (N=86)was
invited to participate in experimental tasks during baseline and post-
treatment to assess biased information processing. These data focus
on different research questions and will be presented separately. Data
presented here were collected between January 2013 and April 2016.
2.4 Interventions
2.4.1 MBCT+ TAU
MBCT was based on the manual by Segal, Williams, and Teasdale
(2002) and consisted of 8 weekly 2.5-hr sessions and 1 day of prac-
tice (day of silence). Participants were enrolled in MBCT courses that
were part of the regular treatment program for patients with depres-
sive disorders. The average number of study participants was 2.41
(SD = 1.55) per MBCT group of 8–12 patients. Mindfulness train-
ers were informed about enrollment of participants in the study, but
were pressed to adopt an identical approach and procedure for all
patients. Group members were not informed about study participa-
tion of individual fellow members, but participants were of course
allowed to share this information at will. All mindfulness trainers were
highly experienced in working with depressed patients and had com-
pleted a postgraduate 2-year mindfulness teacher training. Thereby
they met the advanced criteria of good practice guidelines of the UK
Network for Mindfulness-Based Teachers (Network, 2011). Teacher
competence and adherence was assessed with theMindfulness-Based
Interventions-Teaching Assessment Criteria (Crane et al., 2012) based
on two video recorded sessions per trainer. Two independent mindful-
ness trainers rated the trainers. Mutually agreed ratings of the train-
ers were “proficient” (n = 2), “proficient/competent” (n = 1), “compe-
tent” (n = 2), and “advanced beginner” (n = 1). Videos of two trainers
(who trained, respectively, two and three participants) were unavail-
able. Participants received TAU in conjunction withMBCT.
2.4.2 TAU
Treatment-as-usualTAU was a naturalistic condition consisting of
mental health care for depression, including antidepressant medica-
tion, psychological treatment, support by a psychiatric nurse, or day-
hospital treatment. There were no significant differences between
conditions in the mean number of treatment sessions or in the num-
ber of patients who received these treatments (see Table 2). Medica-
tion levels at baseline canbe found inTable1.Aminority of participants
changed in medication level. This information is summarized in Table 2
and additional information can be found in the Supporting Information
Table 1.
2.5 Outcomemeasures
2.5.1 Primary outcomemeasure
The primary outcome was the level of depressive symptoms assessed
with IDS-SR (Rush,Gullion, Basco, Jarrett, &Trivedi, 1996). The IDS-SR
has good psychometric properties (Rush et al., 1996). The IDS-SR has
previously been used in research on MBCT and is sensitive to change
(Geschwind, Peeters, Huibers, vanOs, &Wichers, 2012). In the current
sample, the internal consistency was 𝛼 = 0.74.
2.5.2 Secondary outcomemeasures
Remission was assessed with the depression module of the MINI,
which investigates depressive symptoms according to DSM-IV crite-
ria. Remission was defined as the absence of depressive symptoms
during the last 2 weeks. Participants reporting some symptoms but
not fulfilling DSM-IV criteria according to the MINI were classified as
being inpartial remission. The interviewswereadministeredby trained
research psychologists supervised by an experienced psychiatrist (AS)
and were audio recorded. For logistical reasons, it was not possible to
keep the research psychologists blind to treatment allocation. A ran-
dom sample (n = 25) of the recorded MINI depression modules was
scored by an independent psychologist blind to condition, who was
extensively trained in the administration of the MINI. This yielded a
high interrater reliability (Cohen's kappa 0.88).
Rumination was assessed with the Ruminative Response Scale
(RRS-EXT; Raes & Hermans, 2007; Schoofs, Hermans, & Raes, 2010).
Quality of life was assessed with theWorld Health OrganizationQual-
ity of Life scale (Skevington, Lotfy, & O'Connell, 2004). Mindfulness
skills and self-compassion were assessed with the Five Facet Mind-
fulness Questionnaire (Baer et al., 2008) and the Self-Compassion
Scale (Neff, 2003), respectively. More information about these sec-
ondary outcome measures can be found in the published study proto-
col (Cladder-Micus et al., 2015, pp. 5–6).
2.6 Statistical analysis
The power calculation was based on a Cohen's d effect size of 0.53
for currently depressed patients as reported in a previous study (van
Aalderen et al., 2011). Based on an 𝛼 of 0.05 and power of 80%,
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TABLE 2 Total number of participants and mean amount of therapy sessions received as treatment-as-usual (TAU) and changes in antidepres-
sant medication from baseline to posttreatment
MBCT+ TAU TAU
N % M SD N % M SD Test
Therapy sessions
Psychologist 23 46.9 4.84 6.59 30 52.6 3.86 4.37 𝜒2(1)= 0.256, P= 0.61
t(92)= –0.859, P= 0.39
Psychiatrist 15 30.6 0.73 1.33 20 35.1 0.72 1.09 𝜒2(1)= 0.178, P= 0.67
t(92)= –0.092, P= 0.97
Occupational therapist/ nurse specialist 8 16.3 1.04 3.12 13 22.8 1.28 2.63 𝜒2(1)= 0.626, P= 0.43
t(92)= 0.395, P= 0.69
Day care treatment 4 9.7 14.5b 11.21 1 1.75 12b 0 Fisher's exact: P= 0.174
t(3)= –0.199, P= 0.855
Medication
Discontinueda 4 8.2 2 3.5
Decrease inmedication level 3 6.1 1 1.8
Increase inmedication level 0 0 4 7.0
Note. Psychologist sessions include therapy sessions lead by a registered psychologist (e.g., CBT, IPT, neuropsychological tests, schema therapy). Sessions by
a psychiatrist include check-up and advice concerning medications. Therapy sessions given by an occupational therapist/nurse specialist include therapies
such as running therapy, rehabilitation modules, and psychomotor therapy. Day care includes outpatient care provided by a mental health care institution
such as day treatment.
aAll antidepressant medication tapered to zero.
bIn days; only including participants with≥1 day of day care treatment.
estimating the correlation between baseline and posttreatment scores
to be 0.5, and expecting a drop-out of 8 participants, a required sam-
ple size of 94 participants emerged (Cladder-Micus et al., 2015). For
the main analysis, posttreatment scores of depressive symptoms were
compared between the two conditions in an analysis of covariance
(ANCOVA), controlling for baseline scores of depression, chronicity
(1–2 years; ≥2 years), and treatment site. Similar analyses were con-
ducted for the secondary outcome measures, controlling for baseline
scores of the respective variable, chronicity (1–2 years; ≥2 years), and
treatment site. A Cohen's d effect size was calculated based on the
total group's (n = 106) standard deviation on the IDS-SR at baseline.
A statistical significance level of 0.05 was adhered to for all analyses.
Moderating effects of gender, age, childhood trauma, number of previ-
ous episodes, duration of current depressive episode treatment resis-
tance, baseline levels of depressive symptoms, rumination, mindful-
ness skills, and self-compassionwere explored in the intention-to-treat
(ITT) sample by incorporating interaction effects in the models. Post-
treatment IDS-SR scores were missing for 10 participants (9.4%, TAU:
n=5,MBCT+TAU:n=5). Therewerenodifferences in clinical orbase-
line characteristics between patients with and without posttreatment
IDS-SR scores, except that the patients with missing scores reported a
higher number of previous depressive episodes (M = 5.00, SD = 8.90,
t (102) = –2.32, P = 0.02) than complete cases (M = 2.45, SD = 2.07).
For two patients without posttreatment scores, follow-up scores were
used. Analyses were based on an ITT approach including all available
data. Next, analyses were repeated in the per-protocol (PP) sample,
including participants of MBCT + TAU who attended ≥4 sessions and
participants of TAU. Sensitivity analyses were performed by imputing
missing data according to the last observation carried forward (LOCF)
technique. IBM SPSS statistics 22was used to analyze the data.
3 RESULTS
3.1 Patient flow
Of the 213 patients who were assessed for eligibility, 111 were
interviewed and 106 were randomized over MBCT + TAU (n = 49)
and TAU (n = 57) (see Figure 1). There were no significant differ-
ences in clinical characteristics or baseline scores between the con-
ditions (see Table 1). Before entering the study, 102 participants had
received > 10 sessions of psychological treatment during the cur-
rent episode, one participant completed nine sessions during the
current depressive episode and > 10 during the previous episode,
and three participants refused psychological treatment because they
received > 10 sessions during the previous depressive episode. Five
participants refused to use antidepressant medication during the
current depressive episode against the advice of their psychiatrist.
All other participants (n = 101) had been using adequate levels of
antidepressant medication for at least 4 weeks. Twenty-six (53.0%)
MBCT + TAU participants completed a second baseline because time
from randomization to MBCT exceeded 4 weeks and no significant
changes in depressive symptomsbetween the first and secondbaseline
were observed (Mbaseline1 =41.15, SDbaseline1 =7.86,Mbaseline2 =40.38,
SDbaseline2 = 9.99; t (25) = 0.47, P = 0.64). None of the participants
of the TAU condition took part in MBCT or other mindfulness-based
training. Twelve participants of the MBCT + TAU condition (24.5%)
attended fewer than four sessions of MBCT and were classified as
non-completers. Theother participants (completers) attendedonaver-
age 7.09 (SD = 1.15) out of the eight MBCT sessions. The most
prevalent reason for drop-out was the occurrence or deterioration of
physical problems (see Figure 1). Non-completers reported a shorter
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F IGURE 1 Consort flow diagram
duration of the current depressive episode (M = 60.05 months,
SD=71.72) than completers (M=93.18months, SD=56.22;U=246.5,
P = 0.005) and they were more often unemployed (𝜒2 (5) = 8.60,
P = 0.04). There were no other significant differences in sociodemo-
graphic or clinical characteristics between non-completers and com-
pleters (see Table 2 in the Supporting Information). No serious adverse
events occurred.
3.2 Primary outcome
Depression scoreswereanalyzed separately for the ITT sample and the
PP sample. In both analyses, theMBCT+ TAU condition showed lower
levels of depressive symptoms than TAU, with small to medium effect
sizes. However, the difference was only significant in the PP sample
(–4.24, 95% CI [–8.38 to –0.11], d = 0.45, P = 0.04) and not in the ITT
sample (–3.23, 95% CI [–7.02 to 0.56], d= 0.35, P= 0.09) (see Table 3).
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Sensitivity analyses using the LOCF sample led to similar findings.
When participants who refused to take antidepressant medication
(n = 5) were excluded from the analyses, results of the ITT sample (–
3.01, 95% CI [–6.8, 0.78], d= 0.31, P = 0.12) and the PP sample (–4.59,
95% CI [–8.8, –0.38], d = 0.51, P = 0.03) were comparable to the main
analyses.
3.3 Secondary outcomes
Compared to TAU, a significantly larger proportion of MBCT + TAU
participants reached remission (MBCT + TAU: 41.5%; TAU: 21.6%,
Table 4). However, most cases were classified as partial remission
(MBCT + TAU: 39.0%; TAU: 17.65%) and a minority as full remission
(MBCT + TAU: 2.44%; TAU: 3.92%). Compared to TAU, the MBCT +
TAU condition showed significantly less rumination (d= 0.39, P= 0.04)
and significantly higher quality of life (d= 0.42, P= 0.048) at posttreat-
ment, controlling for baseline scores. Additionally, participants with
MBCT + TAU showed significantly more mindfulness skills (d = 0.73,
P< 0.001) and significantly more self-compassion (d= 0.64, P= 0.001)
than participants with TAU only. Analyses in the PP sample yielded
comparable results (see Tables 3 and 4).
3.4 Moderation analyses
There were no significant moderators for the effect of condition on
depressive symptoms in the ITT sample, apart from baseline levels of
rumination (F (1, 84)=5.44,P=0.02). Participantswith higher baseline
rumination showed a significantly larger decrease in depressive symp-
toms in theMBCT+TAUcondition compared to TAU,while controlling
for depressive symptoms on baseline. In an exploratory analysis, par-
ticipants were grouped based on a previously published clinical mean
of the RRS-EXT (Raes et al., 2009). In the group of participants scoring
above the clinical mean for rumination, participants assigned toMBCT
+ TAU showed significantly lower depressive symptoms compared to
TAU (–10.79, 95% CI [–15.72 to –5.85], d = 1.64, P < 0.001; MBCT +
TAU n = 17, TAU n = 22) posttreatment while controlling for baseline
depressive symptoms, whereas no difference between MBCT + TAU
and TAU was observed in the group of participants scoring below the
clinical mean (1.47, 95%CI [–4.38 to 7.33], d= 0.24, P= 0.62; MBCT+
TAU n = 22, TAU n = 30). Patients of the MBCT + TAU condition who
scoredhighon treatment resistance (DM-TRD) tended to report higher
levels of depressive symptoms posttreatment, however this difference
was not significant (F (1, 89)= 3.05, P= 0.084).
4 DISCUSSION
The aim of the current study was to investigate the effectiveness of
MBCT+TAU for chronic, treatment-resistant depressed patients, who
had not improved during not only previous pharmacotherapy but also
psychological treatment. The results of the ITT analysis did not confirm
the expected reduction in depressive symptoms. However, completers
of the MBCT + TAU did show a significant decrease in depressive
symptoms compared to TAU. Further, according to the ITT analyses,
more participants in the MBCT + TAU condition reached partial
remission and MBCT + TAU participants reported less rumination
and increased quality of life, mindfulness skills, and self-compassion
compared to participants receiving TAU only.
The finding that the decrease in depressive symptoms was signif-
icant only in the PP analysis and not in the ITT analysis can be partially
explained by the relatively high proportion of patients not completing
MBCT (n = 12, 24.5%). This percentage is comparable to other studies
on MBCT in chronic (27.8%; Michalak, Schultze, Heidenreich, &
Schramm, 2015) or pharmacoresistant depressed patients (22.98%;
Eisendrath et al., 2016), but seems to be higher than in studies
focusing on patients with recurrent depression (8.8%; van Aalderen
et al., 2011). Compared to completers, non-completers reported a
shorter duration of the current depressive episode and were more
often unemployed. This could indicate that a longer duration might
increase psychological burden and thereby motivates patients to
acquire new skills. Additionally, a daily routine could be helpful in
incorporating mindfulness skills into daily life. However, the sample of
non-completers is too small to draw firm conclusions here. Although
one might expect that the most severely depressed patients drop out
of treatment, non-completers and completers did not differ in the
severity of depressive symptoms, number of previous episodes, or age
of onset. By contrast, a noticeable number of non-completers reported
that physical problems (see Figure 1) interfered with participation and
were the reason for discontinuingMBCT.
MBCT + TAU had significant effects on rumination, quality of life,
mindfulness skills, and self-compassion. Following the course, MBCT
+ TAU participants reported less rumination and a higher quality of
life. The increase in mindfulness skills and self-compassion might indi-
cate that chronic, treatment-resistant depressed patients are able to
learn mindfulness meditation techniques and develop a more compas-
sionate and friendlier attitude toward themselves. Although results
of these secondary outcomes should be interpreted as preliminary, as
the power analysis was focused on changes in depressive symptoms,
this may indicate that MBCT + TAU has effects that could be valuable
for chronic, treatment-resistant depressed patients, even if no or only
small changes in depressive symptoms are evoked.
This study is the first to investigate the effectiveness of MBCT +
TAU for chronic, treatment-resistant depressed patients who did not
benefit from pharmacotherapy and psychological treatment. The cur-
rent study has high ecological validity because of its pragmatic design.
Participants were moderately to severely depressed outpatients and
were enrolled inMBCT trainings provided regularly at their local men-
tal health care institution. Thereby this study provides much-needed
insight into the effectiveness rather than efficacy of MBCT, which was
formulated as an important research goal in a recent review paper
of MBCT (Dimidjian & Segal, 2015). However, the effect sizes found
in this study (ITT: d = 0.35; PP: d = 0.45) are smaller than in previ-
ous preliminary studies of chronic or treatment-resistant depressed
patients (Barnhofer et al., 2009; Eisendrath et al., 2008; Kenny &
Williams, 2007), as well as smaller than the effect size found in previ-
ous research on currently depressed patients (d = 0.53; van Aalderen
et al., 2011), whichwas used for our power analysis. Both the relatively
small effect size and the high drop-out rate from MBCT can likely be
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TABLE 4 Number (and percentages) of depression status at posttreatment according to DSM-IV criteria
ITT PP
MBCT+ TAU TAU MBCT+ TAU TAU
n= 41 n= 51 𝝌2 test n= 34 n= 51 𝝌2 test
Major depression 24 (58.5) 40 (78.4) 𝜒2(2)= 4.25, P= 0.039,𝜑= 0.22 19 (55.9) 40 (78.4) 𝜒2(2)= 4.89, P= 0.027,𝜑= 0.24
Remission 17 (41.5) 11 (21.6) 15 (44.1) 11 (21.6)
Full remission 1 (2.44) 2 (3.92) 0 (0) 2 (3.92)
Partial remission 16 (39.0) 9 (17.65) 15 (44.14) 9 (17.65)
Note.Remission is defined as reporting noDSM-IV symptoms of depression during the last 2weeks based on theMINI. Partial remission is defined as report-
ing some symptoms but not fulfillingDSM-IV criteria for amajor depressive disorder. Depression is defined as fulfilling theDSM-IV criteria formajor depres-
sion on theMINI.
explained by the higher severity of symptoms in the current study sam-
ple compared to previous research (van Aalderen et al., 2011). As only
completers showed a significant decrease in depressive symptoms,
obstacles to completing treatment should be investigated in future
research, for example, by conducting qualitative interviews.
In addition to the effectiveness of MBCT, we also investigated pos-
sible moderators of treatment effect. Importantly, levels of rumination
moderated the effect of MBCT + TAU compared to TAU on depres-
sive symptoms. Participants with high levels of rumination benefit-
ted more from MBCT + TAU than TAU. According to the underlying
theoretical model, rumination is an important working mechanism of
MBCT (Segal et al., 2002) andpreviousworkhas indicated that rumina-
tion might mediate the effect of MBCT on depressive symptoms (Sha-
har, Britton, Sbarra, Figueredo, & Bootzin, 2010; van der Velden et al.,
2015). The current study indicates that MBCT could be particularly
helpful for chronic, treatment-resistant depressed patients with high
levels of rumination. However, because of the explorative nature of
the moderation analysis, this finding should be interpreted as prelimi-
nary and requires replication and further investigation. In addition, the
results of the current study showednomoderating effects of childhood
trauma, baseline severity of depression, chronicity, or treatment resis-
tance. Moderating effects of childhood trauma and severity of base-
line symptoms were previously found in recurrent depressed patients
(Ma & Teasdale, 2004; Williams et al., 2014). However, recent studies
onMBCT in chronic or pharmacoresistant depression foundnomoder-
ating effect of these variables (Eisendrath et al., 2016; Michalak et al.,
2016), which is in line with our findings. Taken together, these results
indicate that rumination might be an important moderator in chronic,
treatment-resistant depression, while levels of childhood trauma and
severity of depressive symptoms at baseline appear to be of less
influence.
A limitation of the current study is that MBCT was implemented
as an add-on to TAU. The results in the MBCT + TAU condition could
therefore be partially due to nonspecific therapy effects, such as peer
support, hope, and attention received from the therapist. Additionally,
patients and investigators were not blind to treatment allocation,
which might have been a potential source of bias. Future studies
should compare MBCT to active treatments matched on treatment
intensity and should also investigate long-term effects and cost effec-
tiveness. Furthermore, due to the pragmatic design of the study,MBCT
trainings were not in all cases immediately available after random-
ization. Participants who had to wait more than 4 weeks until the
start of MBCT received a second baseline assessment. This means
that the total duration of the study is not identical for the conditions.
However, one should note that we found no difference in depressive
symptoms between the first and second baseline assessment. In
addition, research designs investigating potential mediators such
as rumination, mindfulness skills, and self-compassion by including
multiple assessments during the course of MBCT would give further
insight intomechanisms of change.
The current study provides several clinical and research implica-
tions. Even though effects on depressive symptoms were not sig-
nificant in the ITT analysis, results of the secondary outcome mea-
sures indicated that MBCT might have beneficial effects for chronic,
treatment-resistant patients on important factors other than depres-
sive symptoms. In addition, the results of thePPanalyses indicated that
completers of MBCT + TAU did show a significantly greater reduction
in depressive symptoms compared to TAU alone. Keeping in mind that
the study sample represents a seriously ill population, small effects
on depressive symptoms accompanied by effects on rumination, qual-
ity of life, mindfulness, and self-compassion may be valuable for an
individual patient. In addition, the relatively low costs and rare side
effects of MBCT compared with other treatment options for this pop-
ulation, for example, intensive pharmacological treatment or electro-
convulsive therapy, should be taken into account in treatment choice.
However, it seems to be important to further investigate reasons why
patients do not complete MBCT. Additionally, future research should
further focus on rumination and other possible working mechanisms
in order to provide researchers and clinicians with more information
about the working mechanisms of MBCT and predictors of treatment
success.
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